Phospholipids
phosphatidic acid PA
Phosphatidylcholine PC
Phosphatidylethanolamine PE
phosphatidylserine PS
phosphatidylglycerol PG
phosphatidylinositol PI
Dietary intake of phospholipids
Dietary intake of phospholipids has diminished due to: - mad cow disease (decrease in brain and liver consumption), - replacement of lecithin in food by other emulsifiers.
Triglycerides between 80 and 120 g Phospholipids 2-3 g instead of 4-6 g
No RDI for phospholipids
It exists no Reference Dietary Intakes (RDI) for phospholipids because we do not know the organism requirements and human body can synthesize them.
Innis et al. 2003, J Pediatr 143: 351-6
=> But for example as you can see in this figure, an excess in synthesis of PC can have a metabolic price: an increase in homocysteine levels.
Classic use of soybean lecithins
Dose g
Duration days
Cholesterolemia Triglyceridemia Reference
1-2 244 No effect No effect 1
6-18 84 Decrease Decrease 2
18 10 No effect No effect 3
1) ter Welle et al. 1974, Acta Med Scand 195: 267-71 2) Brook et al. 1986, Biochem Med Metab Biol 35: 31-9 3) Greten et al. 1980, Atherosclerosis 36: 81-8
Feeding infants with Mother‘s milk is the Best !
The Golden Standard
One of the reason is the presence of LC-PUFA: DHA & ARA
Garcia et al. 2011, J Pediatr Gastroenterol Nutr 53: 206-12
Lipid composition of human milk
3-4 days postpartum 6-10 days postpartum 30 days postpartum
Garcia et al. 2011, J Pediatr Gastroenterol Nutr 53: 206-12
Respective contribution of TG & PL
LC-PUFA ARA DHA Proportion in TG, wt% TFA 0.31 ± 0.18 (0.05-0.76) 0.30 ± 0.28 (0.00-0.95) Proportion in PL, wt% TFA 2.83 ± 1.30 (0.81-4.59) 2.34 ± 0.91 (0.93-4.34)
Contribution of TG, % 90.0 ± 6.5 78.0 ± 32.8 Contribution of PL, % 9.9 ± 6.5 21.9 ± 32.8
Adapted from Table 3: Respective contribution of human milk TG and PL to ARA and DHA supply.
Thus, the contribution of phospholipids can be more important as much than their fatty acids are usually not used for ββ-oxidation.
Feeding infants with Mother‘s milk is the Best !
But, in case this is not possible, you absolutely need to provide DHA and ARA in
form of phospholipids with your formula
For this purpose, only egg yolk lipids bring DHA and ARA in form of phospholipids
similarly to Mother‘s milk lipids
Infant formula
Phosphatidylcholine and alcoholic hepatic steatosis
Baboons
Lieber et al. 1994, Gastroenterology 106: 152-9
=> PC with the dose of 2.8 g/1000 kcal, prevents the development of fibrosis and cirrhosis in baboons following a diet with 50% of caloric ration in form of ethanol.
Baboons with PC
Chronic hepatitis
Gundermann et al. 2011, Pharmacol Rep 63: 643-59
=> This meta-analysis of 9 studies (409 patients) shows global improvement of 26% in the phosphatidylcholine supplemented groups.
PS & PA against mental stress
3 weeks treatment 80 patients 20-45 years old
Hellhammer J et al. Stress 2004, 7: 119-26.
=> The ACTH and cortisol increases, normally induced by stress, are significantly lower with a preventive treatment of 400 mg of phosphatidylserine + phosphatidic acid.
PS & PA against mental stress: results
Hellhammer J et al. Stress 2004, 7: 119-26.
PS & PA against mental stress: results
=> The salivary cortisol increase is also significantly lower with the preventive treatment of 400 mg of phosphatidylserine + phosphatidic acid.
Hellhammer J et al. Stress 2004, 7: 119-26.
Phosphatidylserine levels in tissues
Tissues (human) PS in % of total cell phospholipid
Brain myeline 21
Brain white matter 16
Brain grey matter 13
Retina 8-16
Red blood cells 14
Platelets 9
Lung, spleen, amniotic fluid 8
Liver, heart, skeletal muscle 3
Kidney 1
Plasma Traces
First source of phosphatidylserine
Firstly, phosphatidylserine was manufactured from cerebral cortex of beef.
PS and cognitive decline
Patients (n)
Age years
PS dose in mg
Time weeks
Beneficial effects Ref
149 50-75 300 12 Amelioration of 3/5 tests in patients and 4/5 among most
affected patients
1
425 65-93 300 26 Amelioration in behaviour and cognitive parameters
2
1) Crook et al. Neurology 1991, 41 : 644-9 2) Cenacchi et al. Aging 1993, 5 : 123-33
PS and cognitive decline
Patients (n)
Age years
PS dose in mg
Time weeks
Beneficial effects Ref
149 50-75 300 12 Amelioration of 3/5 tests in patients and 4/5 among most
affected patients
1
425 65-93 300 26 Amelioration in behaviour and cognitive parameters
2
120 > 57 300 or 600
12 No significant amelioration 3
1) Crook et al. Neurology 1991, 41 : 644-9 2) Cenacchi et al. Aging 1993, 5 : 123-33 3) Jorissen et al. Nutr Neurosci 2001, 4 : 121-34
Phosphatidylserine manufacturing
- bacteria (more stable with less residual activity) - vegetable (cabbage)
PS and cognitive decline
Patients (n)
Age years
PS dose in mg
Time weeks
Beneficial effects Ref
149 50-75 300 12 Amelioration of 3/5 tests in patients and 4/5 among most
affected patients
1
425 65-93 300 26 Amelioration in behaviour and cognitive parameters
2
120 > 57 300 or 600
12 No significant amelioration 3
78 50-69 100 or 300
26 Amelioration of memory in patients with memory
complaints
4
1) Crook et al. Neurology 1991, 41 : 644-9 2) Cenacchi et al. Aging 1993, 5 : 123-33 3) Jorissen et al. Nutr Neurosci 2001, 4 : 121-34 4) Kato-Kataoka et al. J Clin Biochem Nutr 2010, 47 : 246-55
Sources to manufacture the PS
Generally, soy phospholipids (rich in phosphatidylcholine) are used as raw material. There is also a new PS available, made from sunflower phospholipids.
Moreover, marine or egg yolk sources can be used (because they are also rich in phosphatidylcholine) as raw material to obtain phosphatidylserine containing omega 3.
PS-DHA/EPA and cognitive decline
Patients (n)
Age years
Dose PS-DHA/EPA
in mg
Time weeks
Beneficial effects Ref
8 (pilot study)
≥ 60 300-37.5 6 Amelioration of memory among patients with memory
complaints
1
157 50-90 300-79 15 Amelioration of memory among patients with memory
complaints
2
1) Richter et al. Clin Interv Aging 2010, 5 : 313-6 2) Vakhapova et al. Dement Geriatr Cogn Disord 2010, 29 : 467-74
Alpha linolenic acid (ALA, C18:3 ω3)
Eicosapentaenoic acid (EPA, C20:5 ω3)
Docosahexaenoic acid (DHA, C22:6 ω3)
Main omega 3 fatty acids
40
Polyunsaturated fatty acid metabolism
18:2 ωω6
18:3 ωω6
20:3 ωω6
20:4 ωω6
22:4 ωω6
22:5 ωω6
ΔΔ 12 DS
E
24:4 ωω6
24:5 ωω6
Mammals
- Plants - Invertebrates
E AA
LA
18:1 ωω9
E
ββ-ox
Endoplasmic reticulum
Peroxisome
DS = Desaturase E = Elongase ββ-ox = ββ-oxidation
Arachidonic acid
18:3 ωω3
18:4 ωω3
20:4 ωω3
20:5 ωω3
22:5 ωω3
22:6 ωω3
ΔΔ 15 DS
24:5 ωω3
24:6 ωω3
E
E EPA
DHA
ALA
E
ββ-ox
Eicosapentaenoic acid
Docosahexaenoic acid
ΔΔ 6 DS
ΔΔ 5 DS
ΔΔ 6 DS
Strong competition for ΔΔ6 desaturase
18:3 ωω3
18:4 ωω3
22:6 ωω3
18:2 ωω6
18:3 ωω6
22:5 ωω6
24:5 ωω3
24:6 ωω3 24:4 ωω6
24:5 ωω6
DHA
LA ALA
ββ-ox
Endoplasmic reticulum
Peroxisome DS = Desaturase ββ-ox = ββ-oxidation
ββ-ox
SA GLA
DPA
24:6 ωω3 24:5 ωω6
ΔΔ6 DS Conversion < 1%
Omega 3 levels in human tissues
DHA is the most abundant omega 3 fatty acid in human cell membranes because this fatty acid is essential for the cell functionality.
Arterburn et al. 2006, Am J Clin Nutr 83: 1467S-76S
DHA and erythrocyte deformability Animal supplementation study
=> Supplementation with DHA induces an accretion of DHA in erythrocyte membranes resulting in a better deformability, contrary to supplementation with EPA, which can counteract this effect.
Poschl JM et al. Thromb Res 81: 283-8, 1996
Phosphatidylcholine DHA (PC-DHA)
500 ps dynamics of PC (C18:0 and DHA), courtesy from Dr. Scott Feller
A similar bioavailability
DHA 8mg/kg 40 days in female rats
Plasma µµg/ml
Erythrocyte mg/g PL
Hepatic tissue mg/g PL
Adipose tissue
mg/g lipids Placebo (olive oil) 80 12.5 45 4.5
Phospholipids 150 (+90%) 27.5 (+120%) 90 (+100%) 9 (+100%)
Monoacylglycerides* 160 (+100%) 25 (+100%) 80 (+80%) 8.5 (+90%)
Triglycerides** 145 (+80%) 22.5 (+80%) 70 (+55%) 7 (+55%)
Ethyl esters*** 150 (+90%) 17.5 (+40%) 40 (-10%) 5 (+10%)
* Not available in the market ** Available as fish or micro-algae oils *** Available as medical drug (for example Omacor®)
Animal supplementation study
Valenzuela A et al. Ann Nutr Metab 49: 325-32, 2005
A better bioaccretion in tissue membranes
DHA 8mg/kg 40 days in female rats
Plasma µµg/ml
Erythrocyte mg/g PL
Hepatic tissue mg/g PL
Adipose tissue
mg/g lipids Placebo (olive oil) 80 12.5 45 4.5
Phospholipids 150 (+90%) 27.5 (+120%) 90 (+100%) 9 (+100%)
Monoacylglycerides* 160 (+100%) 25 (+100%) 80 (+80%) 8.5 (+90%)
Triglycerides** 145 (+80%) 22.5 (+80%) 70 (+55%) 7 (+55%)
Ethyl esters*** 150 (+90%) 17.5 (+40%) 40 (-10%) 5 (+10%)
* Not available in the market ** Available as fish or micro-algae oils *** Available as medical drug (for example Omacor®)
Animal supplementation study
Valenzuela A et al. Ann Nutr Metab 49: 325-32, 2005
A better bioaccretion into brain
=> Less than 1% of the ingested dose of DHA was found in brain and the phospholipids form permits a two-fold accretion in older rats when compared to triglyceride form.
Graf et al. 2010, Prostaglandins Leukot Essent Fatty Acids 83: 89-96
A better resistance to oxidation In vitro study
=> DHA in the form of phospholipids is more resistant to the oxidative degradation than DHA in the form of triglycerides or ethyl esters.
Song et al. 1997, Biosci Biotechnol Biochem 61: 2085-8
-97%
-64%
-10%
To resume
DHA form Triglycerides Ethyl esters Phospholipids History of human consumption
++ - ++
Bioaccretion + +/- ++ Oxidative stability -- - ++ Choline - - ++ Phosphorus - - ++
=> Phospholipids are the better form to bring DHA to human organism.
Health applications of Krill oil
Krill oil Premenstrual syndrome2
Hyperlipidemia1
Inflammation/arthritis3
1) Bunea R et al. Altern Med Rev 2004, 9: 420-8 2) Sampalis F et al. Altern Med Rev 2003, 8: 171-9 3) Deutsch L J Am Coll Nutr 2007, 26: 39-48
Marine phospholipids: comparison
Raw materials Krill Caviar History of human consumption
- ++
Oxidation stability ++ ++ Taste impact - - Choline ++ ++ EPA ++ + DHA + ++ Astaxanthin ++ ++ Vitamin E + + Bioavailability + +
=> Caviar phospholipids extracted from fish eggs present higher DHA levels than phospholipids extracted from Krill.
Marine phospholipids & psoriasis
Dupont 2006, Phytothérapie 1: 15-22
6 months of treatment
with 400 mg daily
Top Related